2-Propenamide, N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-
| Title | Journal |
|---|---|
| Structure-based optimization of click-based histone deacetylase inhibitors. | European journal of medicinal chemistry 20110801 |
| Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. | Journal of medicinal chemistry 20110714 |
| Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. | Leukemia research 20110301 |
| Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824). | Journal of medicinal chemistry 20100408 |
| Chemical phylogenetics of histone deacetylases. | Nature chemical biology 20100301 |
| Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20091001 |
| Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081015 |
| Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. | Blood 20081001 |
| Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). | International journal of oncology 20081001 |
| Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. | Molecular cancer therapeutics 20081001 |
| Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. | World journal of gastroenterology 20080621 |
| Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. | Neuro-oncology 20080601 |
| Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080515 |
| Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. | Neoplasia (New York, N.Y.) 20080401 |
| Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. | Bioorganic & medicinal chemistry letters 20080315 |
| Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. | Journal of molecular medicine (Berlin, Germany) 20080101 |
| Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. | Journal of medicinal chemistry 20071115 |
| The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. | Cancer research 20071001 |
| Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. | World journal of gastroenterology 20070921 |
| HDAC inhibitors and cardiac safety. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070201 |
| Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. | Molecular cancer therapeutics 20070101 |
| Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells. | Cancer chemotherapy and pharmacology 20061101 |
| Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. | Cancer research 20060901 |
| In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. | Cancer research 20060801 |
| The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. | Molecular pharmacology 20060101 |
| Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells. | Molecular cancer therapeutics 20051101 |
| Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. | Molecular cancer therapeutics 20050901 |
| Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. | Leukemia 20041201 |
| The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. | Cancer research 20040915 |
| Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040801 |
| In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. | Biochemical pharmacology 20040701 |
| Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. | Haematologica 20040401 |
| Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. | Cancer research 20040115 |
| The discovery of NVP-LAQ824: from concept to clinic. | Current medicinal chemistry 20031101 |
| N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). | Journal of medicinal chemistry 20031009 |
| NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. | Blood 20031001 |
| Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. | Molecular cancer therapeutics 20031001 |
| Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. | Cancer research 20030815 |